For patients at a high risk for type 2 diabetes, the mild NSAID salsalate, a nonacetylated salicylate, may help fend off the disease, investigators here believe.

A month of inexpensive salsalate led to significant reductions in fasting glucose, glycemic response, and glycated albumin, compared with placebo, in obese nondiabetic adults, Allison B. Goldfine, M.D., of Harvard and the Joslin Diabetes Center, and colleagues reported in the February issue of Diabetes Care.[more]